Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A First-in-Human Study for BAF312: A Two Parts, Single Center, Randomized, Double-Blind, Placebo-Controlled Ascending Single Dose Study to Explore the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral BAF312 in Healthy Volunteers

NCT00422175 is registered in ClinicalTrials.gov with Novartis as lead sponsor.

NCT NCT00422175
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00422175 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A First-in-Human Study for BAF312: A Two Parts, Single Center, Randomized, Double-Blind, Placebo-Controlled Ascending Single Dose Study to Explore the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral BAF312 in Healthy Volunteers
Lead sponsor
Novartis
Phase
Phase 1
Overall status
Completed
Start date
October 31, 2006
Completion date
November 30, 2007
Enrollment
63
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy